Immunofluorescence analysis of HER-2/ErbB2 was performed using 90% confluent log phase SK-OV-3 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with HER-2/ErbB2 (EP1045Y) Rabbit Monoclonal Antibody (MA5-14488) at 2 µg/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conj µgate (A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing localization in the membrane. Panel e shows the no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Human|
|Published species reactivity||Human, Mouse, Not Applicable|
|Host / Isotype||Rabbit|
|Immunogen||A synthetic peptide corresponding to the c-terminus of human Her2|
|Storage buffer||tissue culture supernatant|
|Contains||15mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunocytochemistry (ICC)||2 µg/ml|
|Immunofluorescence (IF)||2 µg/ml|
|Immunohistochemistry (Frozen) (IHC (F))||1:100|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
|Western Blot (WB)||1-3 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-14488 targets HER-2 in IHC (P, F) applications and shows reactivity with Human samples.
The MA5-14488 immunogen is a synthetic peptide corresponding to the c-terminus of human Her2.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
MA5-14488 was used in immunohistochemistry to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast
|Kapucuo¿lu N,Bozkurt KK,Ba¿p¿nar ¿,Koçer M,Ero¿lu HE,Akdeniz R,Akçil M||Pathology, research and practice (211:740)||2015|
Quantitation of fixative-induced morphologic and antigenic variation in mouse and human breast cancers.
MA5-14488 was used in immunohistochemistry to study the effect of different classes of fixative on the morphology and immunoreactivity of murine anfd human breast cancer specimens using quantitative image analysis
|Cardiff RD,Hubbard NE,Engelberg JA,Munn RJ,Miller CH,Walls JE,Chen JQ,Velásquez-García HA,Galvez JJ,Bell KJ,Beckett LA,Li YJ,Borowsky AD||Laboratory investigation; a journal of technical methods and pathology (93:480)||2013|
STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer.
MA5-14488 was used in immunohistochemistry to study the mechanism by which STAT3 promotes the progression of breast cancer and its utility as a predictor of overall survival
|Chen Y,Wang J,Wang X,Liu X,Li H,Lv Q,Zhu J,Wei B,Tang Y||Journal of breast cancer (16:40)||2013|
The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas.
MA5-14488 was used in immunohistochemistry to study the prognostic utility of ABCG2 immunohistochemical expression in breast carcinomas
|Omran OM||Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer (31:367)||2013|
Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma.
MA5-14488 was used in immunohistochemistry - paraffin section to report the clinicopathological features of 9 breast malignant fibrous histiocytoma patients
|Qiu SQ,Wei XL,Huang WH,Wu MY,Qin YS,Li YK,Zhang GJ||Scientific reports (3:null)||2013|
Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells.
MA5-14488 was used in immunocytochemistry, immunohistochemistry, and western blot to study the killing of HER2-positive cancer cells and cancer stem cells by a combination of trastuzumab and salinomycin treatment of MCF-7 mammospheres
|Oak PS,Kopp F,Thakur C,Ellwart JW,Rapp UR,Ullrich A,Wagner E,Knyazev P,Roidl A||International journal of cancer (131:2808)||2012|